Back to discover
Drug

Pyrrolidonecarboxylic Acid

In clinical development
Emerging researchLate-stage development
Also known as (-)-2-pyrrolidone-5-carboxylic acid, (S)-(-)-2-pyrrolidone-5-carboxylic acid, (S)-pyroglutamic acid, 5-L-oxoproline+11 more

(-)-2-pyrrolidone-5-carboxylic acid, (S)-(-)-2-pyrrolidone-5-carboxylic acid, (S)-pyroglutamic acid, 5-L-oxoproline, 5-Pyrrolidone-2-carboxylic acid, 5-oxo-2-pyrrolidinecarboxylic acid, 5-oxo-L-proline, Glutimic acid, L-5-Pyrrolidone-2-carboxylic acid, L-pyroglutamic acid, L-pyrrolidone carboxylic acid, PCA, PIDOLIC ACID, Pyroglutamic acid, PYRROLIDONE CARBOXYLIC ACID.

1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effect of Tab Block and Patient Controlled Analgesia in Cesarean Section

Clinical trial2021-04-01Completed · ClinicalTrials.gov

Effect of Continue Rhomboid Intercostal and Subserratus Plane Block in Thorocotomy

Clinical trial2021-02-15Completed · ClinicalTrials.gov

Effectiveness of Quadratus Lumborum Block After Nephrectomy

Clinical trial2019-08-25Completed · ClinicalTrials.gov

Hypokalemia and Intravenous Patient Controlled Analgesia

Clinical trial2010-12-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Pyrrolidonecarboxylic Acid
Aliases & brands
(-)-2-pyrrolidone-5-carboxylic acid(S)-(-)-2-pyrrolidone-5-carboxylic acid(S)-pyroglutamic acid5-L-oxoproline5-Pyrrolidone-2-carboxylic acid5-oxo-2-pyrrolidinecarboxylic acid5-oxo-L-prolineGlutimic acidL-5-Pyrrolidone-2-carboxylic acidL-pyroglutamic acidL-pyrrolidone carboxylic acidPCAPIDOLIC ACIDPyroglutamic acidPYRROLIDONE CARBOXYLIC ACID
RxNorm CUI
9036
ChEMBL ID
CHEMBL397976
UNII
SZB83O1W42

Clinical trials

13 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
13
registered trials across all phases
LATEST COMPLETION 2024
12
Late-stage (III+)
10
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 13
Phase 11Phase 31Phase 43Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes4
Food Preferences1Gastrointestinal Hormones1Longevity1Tachykinins1
Journals, researchers & institutions
Top journals
  • Nature metabolism1
Leading researchers
  • Ahrentløv N1
  • Frederiksen AS1
  • Halberg KV1
  • Imig C1
  • John A1
  • Koyama T1
  • Kubrak O1
  • Lassen M1
Leading institutions
free-text, unnormalised
  • The Novo Nordisk Foundation1
  • University of Copenhagen1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials